title: A clinical and pathologic comparison between stage-matched endometrial intraepithelial carcinoma and uterine serous carcinoma: is there a difference?
abstract: Endometrial intraepithelial carcinoma (EIC) is a rare pathologic variant of uterine serous carcinoma (USC). Our aim is to distinguish patterns of clinic-pathologic outcomes in patients with EIC and USC for disease limited to the endometrium (stage 1A) as well as with distant metastasis (stage 4B). Surgically staged patients were retrospectively identified and relevant variables were extracted and compared. Kaplan-Meier was used to generate the survival data. More USC (n = 29) exhibited lymphovascular invasion (stage 4, P = .01) and expressed higher levels of estrogen receptor-α than EIC (P = .0009 and .063 for stages 1 and 4, respectively). The survival is comparable, with 1 recurrence in each group for stage 1A disease. For stage 4 EIC and USC, the progression-free survival (14 vs10 months) and overall survival (19 vs 20 months) are similar to what is previously published. In conclusion, EIC, whether limited to the endometrium, or widely metastatic, imparts similar outcomes and should be treated comparably with stage-matched USC.
authors.affiliation: 1Division of Gynecology Oncology, Department of Obstetrics & Gynecology and Women's Health, Albert Einstein College of Medicine and Montefiore Medical Center, Bronx, NY, USA.
authors.forename: June Y
authors.initials: JY
authors.lastname: Hou
authors.forename: Thomas C
authors.initials: TC
authors.lastname: McAndrew
authors.forename: Gary L
authors.initials: GL
authors.lastname: Goldberg
authors.forename: Kathleen
authors.initials: K
authors.lastname: Whitney
authors.forename: Shohreh
authors.initials: S
authors.lastname: Shahabi
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis; D002278:Carcinoma in Situ / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D018450:Disease Progression; D018572:Disease-Free Survival; D016889:Endometrial Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000601:surgery; D047628:Estrogen Receptor alpha / Q000032:analysis; D005260:Female; D006801:Humans; D053208:Kaplan-Meier Estimate; D008875:Middle Aged; D009361:Neoplasm Invasiveness; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000737:chemistry / Q000401:mortality / Q000556:secondary* / Q000601:surgery; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D014594:Uterine Neoplasms / Q000737:chemistry / Q000401:mortality / Q000473:pathology* / Q000601:surgery
chemical_list: D014408:Biomarkers, Tumor; C506487:ESR1 protein, human; D047628:Estrogen Receptor alpha
keywords: EIC; USC; serous intraepithelial carcinoma; uterine serous carcinoma
references.citation: Am J Surg Pathol. 2000 Jun;24(6):797-806
references.pmid: 10843281
references.citation: J Clin Oncol. 2003 Nov 15;21(22):4200-6
references.pmid: 14615448
references.citation: Cancer. 2003 Jul 1;98(1):176-86
references.pmid: 12833470
references.citation: Gynecol Oncol. 2008 Jan;108(1):201-6
references.pmid: 17997145
references.citation: Hum Pathol. 1995 Nov;26(11):1260-7
references.pmid: 7590702
references.citation: Major Probl Pathol. 1979;12:1-580
references.pmid: 537399
references.citation: Gynecol Oncol. 2007 Jun;105(3):677-82
references.pmid: 17355889
references.citation: Int J Gynecol Pathol. 1995 Jan;14(1):30-8
references.pmid: 7883423
references.citation: Anticancer Res. 2007 Mar-Apr;27(2):1213-7
references.pmid: 17465265
references.citation: Clin Obstet Gynecol. 2011 Jun;54(2):278-91
references.pmid: 21508697
references.citation: Gynecol Oncol. 1994 Sep;54(3):264-8
references.pmid: 8088602
references.citation: Br J Cancer. 2006 Mar 13;94(5):642-6
references.pmid: 16495918
references.citation: Gynecol Oncol. 1996 Oct;63(1):28-33
references.pmid: 8898164
references.citation: Appl Immunohistochem Mol Morphol. 2010 Jan;18(1):75-9
references.pmid: 19956063
references.citation: Int J Gynecol Pathol. 2007 Jan;26(1):38-52
references.pmid: 17197896
references.citation: Gynecol Oncol. 1990 Apr;37(1):112-9
references.pmid: 2323606
references.citation: Am J Surg Pathol. 1995 Apr;19(4):417-32
references.pmid: 7694943
references.citation: Gynecol Oncol. 2009 Oct;115(1):142-153
references.pmid: 19592079
references.citation: Gynecol Oncol. 2003 Dec;91(3):463-9
references.pmid: 14675663
references.citation: Am J Obstet Gynecol. 2008 Feb;198(2):218.e1-6
references.pmid: 18226630
references.citation: Mod Pathol. 2005 Jan;18(1):75-82
references.pmid: 15389257
references.citation: Cancer. 2009 May 15;115(10):2119-27
references.pmid: 19306417
references.citation: Cancer. 2006 Nov 1;107(9):2197-205
references.pmid: 17001661
references.citation: Gynecol Oncol. 2005 Dec;99(3):557-63
references.pmid: 16154185
references.citation: Gynecol Oncol. 1995 Dec;59(3):384-9
references.pmid: 8522260
references.citation: Gynecol Oncol. 2005 Mar;96(3):579-82
references.pmid: 15721397
references.citation: Curr Opin Obstet Gynecol. 2010 Feb;22(1):21-9
references.pmid: 19952744
references.citation: Am J Surg Pathol. 1982 Mar;6(2):93-108
references.pmid: 7102898
references.citation: Gynecol Oncol. 2012 Jan;124(1):21-5
references.pmid: 22035806
references.citation: Am J Surg Pathol. 1992 Jun;16(6):600-10
references.pmid: 1599038
references.citation: Curr Opin Obstet Gynecol. 2008 Feb;20(1):20-5
references.pmid: 18197001
references.citation: Gynecol Oncol. 2003 Dec;91(3):470-5
references.pmid: 14675664